Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

317.25 -15.67 (-4.71%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	332,283
Open	332.74
Bid (Size)	300.00 (100)
Ask (Size)	324.55 (100)
Prev. Close	332.92
Today's Range	315.42 - 333.52
52wk Range	26.70 - 335.75
Shares Outstanding	44,712,538
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress ↗

February 14, 2026

Praxis Precision Medicines develops therapies for central nervous system disorders, with candidates targeting depression and epilepsy.

Via The Motley Fool

Soleus Adds a Significant Number of Celcuity Shares ↗

February 13, 2026

This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment.

Via The Motley Fool

Performance

YTD	+10.8%	+10.8%
1 Month	+6.6%	+6.6%
3 Month	+60.6%	+60.6%
6 Month	+580.4%	+580.4%
1 Year	+249.5%	+249.5%

More News

Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

February 09, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 04, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market

January 22, 2026

Via MarketMinute

Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy

January 13, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress

January 12, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 09, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

January 08, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

January 06, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

January 06, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Why Praxis Precision Medicines Stock Popped Today ↗

December 29, 2025

Via The Motley Fool

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

December 29, 2025

Via MarketMinute

Praxis Stock Surges On FDA Breakthrough Status For Essential Tremor Drug ↗

December 29, 2025

Via Benzinga

Traders are paying attention to the gapping stocks in Monday's session. ↗

December 29, 2025

Via Chartmill

Why Did Praxis Precision Stock Surge 12% Pre-Market Today? ↗

December 29, 2025

Via Stocktwits

Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor

December 29, 2025

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026

December 11, 2025

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy

December 09, 2025

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies

December 08, 2025

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

What's going on in today's session ↗

December 05, 2025

Via Chartmill

Top movers analysis in the middle of the day on 2025-12-05: top gainers and losers in today's session. ↗

December 05, 2025

Via Chartmill

The market is filled with gapping stocks in Friday's session. ↗

December 05, 2025

Via Chartmill

What's going on in today's pre-market session ↗

December 05, 2025

Via Chartmill

Why Did PRAX Stock Rocket 24% Pre-Market Today? ↗

December 05, 2025

Via Stocktwits

Frequently Asked Questions

Is Praxis Precision Medicines, Inc. - Common Stock publicly traded?

Yes, Praxis Precision Medicines, Inc. - Common Stock is publicly traded.

What exchange does Praxis Precision Medicines, Inc. - Common Stock trade on?

Praxis Precision Medicines, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Praxis Precision Medicines, Inc. - Common Stock?

The ticker symbol for Praxis Precision Medicines, Inc. - Common Stock is PRAX on the Nasdaq Stock Market

What is the current price of Praxis Precision Medicines, Inc. - Common Stock?

The current price of Praxis Precision Medicines, Inc. - Common Stock is 317.25

When was Praxis Precision Medicines, Inc. - Common Stock last traded?

The last trade of Praxis Precision Medicines, Inc. - Common Stock was at 02/13/26 04:00 PM ET

What is the market capitalization of Praxis Precision Medicines, Inc. - Common Stock?

The market capitalization of Praxis Precision Medicines, Inc. - Common Stock is 14.19B

How many shares of Praxis Precision Medicines, Inc. - Common Stock are outstanding?

Praxis Precision Medicines, Inc. - Common Stock has 14B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.